INSM-18

N/A

Report date: 2022/03/10 20:00:32
NME

Base Information

Drug NameINSM-18
Drug Alias NameINS-18INSM-18TT-100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor tyrosine-protein kinase erbB antagonistsInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptorReceptor tyrosine-protein kinase erbB
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInsmed
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInsmedUniversity Of California
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank